focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.21
Bid: 2.21
Ask: 2.29
Change: -0.045 (-1.96%)
Spread: 0.08 (3.62%)
Open: 2.35
High: 2.37
Low: 2.21
Prev. Close: 2.295
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

Mon, 25th Mar 2024 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 36% at 2.61 pence, 12-month range 0.82p-3.80p. The drug discovery and development company updates on Incanthera PLC's commercial skincare deal, announced in December 2023, with Marionnaud, part of the AS Watson Group. Says the first order from Marionnaud has now doubled to 50,000 units due to the strong demand anticipated by Marionnaud's management. The first order, on track to be delivered during the second quarter of 2024, will generate around GBP2 million in revenue for Incanthera, ImmuPharma said. ImmunPharma holds an 11% stake in Incanthera. ImmuPharma Chief Operating Officer Tim Franklin comments: "As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera's revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company's revolutionary skincare range and its partnership with Marionnaud."

----------

Caspian Sunrise PLC, up 26% at 3.28p, 12-month range 2.20p-7.49p. The Kazakhstan-focused oil and gas exploration and production company said it was mulling the sale of all or part of the BNG contract area's shallow structures at "indicative prices potentially significantly greater than its current carrying value". Says any deal would likely require shareholder approval due to its size of the transaction value relative to the group. "We believe this heightened level of corporate interest in BNG's producing shallow structures is in part the result of the changes last year to the Kazakh oil trading regulations, which now require the production of oil to obtain a trading licence, and the relative scarcity of producing fields with full production licences. The sharp reduction in the discount for international sales referred to below may also have had an effect," the company says. Caspian Sunrise says no binding agreements have been entered into and there is no certainty that discussions will lead to a firm offer or that the board would put an offer before shareholders.

----------

AIM - LOSERS

----------

Aeorema Communications PLC, down 19% at 60.5p, 12-month range 55.00p-119.40p. In the six months that ended December 31, swings to pretax loss of GBP243,534 from a profit of GBP326,021 a year earlier. Revenue falls to GBP6.6 million from GBP7.1 million, while administrative expenses rise to GBP1.7 million from GBP1.2 million. Expects full-year revenue of no less than GBP19 million compared to GBP20.2 million in the financial year that ended June 30, 2023. Chair Mike Hale comments: "With a focus on adaptability and forward planning, Aeorema is well positioned for the future and is confident in its ability to deliver sustainable growth and value creation over the long term. We also expect to reaffirm our commitment to shareholders by maintaining our dividend policy. While this half year's financial performance reflects the impact of project timing, we are encouraged by the underlying strength of our business and our pipeline. Our focus remains steadfast on delivering creative brilliance for our clients on a global scale, and sustained growth and value to our shareholders."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
20 Dec 2021 11:41

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Read more
20 Dec 2021 11:22

ImmuPharma raises £3.55m to fund research pipeline

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced subscriptions and a placing to raise £3.55m on Monday, to fund its research and development pipeline as well as general working capital.

Read more
20 Dec 2021 10:15

ImmuPharma surges after raise at "significant premium" to share price

ImmuPharma surges after raise at "significant premium" to share price

Read more
29 Nov 2021 20:45

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

Read more
29 Nov 2021 13:32

ImmuPharma signs two-year collaboration deal with Imperial College

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Monday that it has signed a two-year collaboration agreement with Imperial College London.

Read more
18 Nov 2021 20:53

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

Read more
18 Nov 2021 15:16

ImmuPharma reports 'significant' progress since restructure

(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported "significant" positive progress on Thursday, following major changes to its board and a restructuring of senior management in August.

Read more
1 Oct 2021 11:47

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

Read more
29 Sep 2021 20:31

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

Read more
29 Sep 2021 13:22

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

Read more
24 Aug 2021 15:08

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

Read more
12 Aug 2021 14:17

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

Read more
12 Aug 2021 13:02

FDA gives ImmuPharma go-ahead for pharmacokinetic study

(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Thursday that the United States Food and Drug Administration (FDA) has approved the start of the pharmacokinetic study as part of its new, "optimised" international phase 3 trial of 'Lupuzor'.

Read more
30 Jul 2021 15:34

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

Read more
16 Jul 2021 11:24

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.